Molecular markers of prostate cancer outcome

European Journal of Cancer

Volumn 41, Issue 6, 2005, Pages 858-887

  Quinn, David I ^a,c   Henshall, Susan M ^b,c   Sutherland, Robert L ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Molecular markers; Oncogenes; Prognosis; Prostate cancer; Tumor suppressor genes

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P16INK4A; PROTEIN P53; TUMOR MARKER; UVOMORULIN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CELL ADHESION; CELL DEATH; CELL PROLIFERATION; DISEASE MARKER; DNA MICROARRAY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 16244376500     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.035     Document Type: Article

References (415)

1. M.W. Kattan, J.A. Eastham, and A.M. Stapleton A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771
2. M.W. Kattan, T.M. Wheeler, and P.T. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499 1507
3. D.I. Quinn, S.M. Henshall, and A.-M. Haynes Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models J Clin Oncol 19 2001 3692 3705
4. D.I. Quinn, S.M. Henshall, and P.C. Brenner Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy Cancer 97 2003 1884 1893
5. M.W. Kattan, M.J. Zelefsky, and P.A. Kupelian Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer J Clin Oncol 21 2003 4568 4571
6. M. Graefen, P.I. Karakiewicz, and I. Cagiannos Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer J Clin Oncol 20 2002 951 956
7. M. Graefen, P.I. Karakiewicz, and I. Cagiannos International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy J Clin Oncol 20 2002 3206 3212
8. D.G. Bostwick, D.J. Grignon, and M.E. Hammond Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 2000 995 1000
9. S.M. Henshall, D.E. Afar, and K.K. Rasiah Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer Oncogene 22 2003 6005 6012
10. S.M. Henshall, D.E. Afar, and J. Hiller Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse Cancer Res 63 2003 4196 4203
11. L. Horvath, and S. Henshall The application of tissue microarrays to cancer research Pathology 33 2001 125 129
12. J.B. Welsh, L.M. Sapinoso, and S.G. Kern Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum Proc Natl Acad Sci USA 100 2003 3410 3415
13. M.L. Cher, K. Chew, and W. Rosenau Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression Prostate 26 1995 87 93
14. A.A. Keshgegian, E. Johnston, and A. Cnaan Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma Am J Clin Pathol 110 1998 443 449
15. M.E. Harper, E. Glynne-Jones, and L. Goddard Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters Prostate 20 1992 243 253
16. R. Nemoto, H. Kawamura, and I. Miyakawa Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma J Urol 149 1993 165 169
17. L. Bubendorf, G. Sauter, and H. Moch Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy J Pathol 178 1996 437 441
18. M.L. Cher, R.A. Stephenson, and B.C. James Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN + M0) prostate cancer J Urol 155 1996 1674 1677
19. L. Cheng, T.M. Pisansky, and T.J. Sebo Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression Clin Cancer Res 5 1999 2820 2823
20. V.S. Khoo, A. Pollack, and D. Cowen Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy Prostate 41 1999 166 172
21. L. Bubendorf, C. Tapia, and T.C. Gasser Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer Hum Pathol 29 1998 949 954
22. E.H. Oomens, G.J. van Steenbrugge, and T.H. van der Kwast Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma J Urol 145 1991 81 85
23. G.D. Grossfeld, A.F. Olumi, and J.A. Connolly Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity J Urol 159 1998 1437 1443
24. T.M. Wheeler, E. Rogers, and M. Aihara Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer J Cell Biochem Suppl 19 1994 202 207
25. M. Aihara, P.T. Scardino, and L.D. Truong The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate Cancer 75 1995 522 529
26. A.M. Stapleton, P. Zbell, and M.W. Kattan Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery Cancer 82 1998 168 175
27. R.A. Weinberg The retinoblastoma protein and cell cycle control Cell 81 1995 323 330
28. C.J. Sherr, and J.M. Roberts Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev 9 1995 1149 1163
29. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1677
30. H. Toyoshima, and T. Hunter p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 Cell 78 1994 67 74
31. M. Hall, S. Bates, and G. Peters Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins Oncogene 11 1995 1581 1588
32. K.F. Macleod, N. Sherry, and G. Hannon p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage Genes Dev 9 1995 935 944
33. J. LaBaer, M.D. Garrett, and L.F. Stevenson New functional activities for the p21 family of CDK inhibitors Genes Dev 11 1997 847 862
34. R.L. Sutherland, and E.A. Musgrove Cyclin E and prognosis in patients with breast cancer N Engl J Med 347 2002 1546 1547
35. INK4a/CDKN2A tumor suppressor and its relatives Biochim Biophys Acta 1378 1998 F115 F177
36. W.H. Liggett, and D. Sidransky Role of the p16 tumor suppressor gene in cancer J Clin Oncol 16 1998 1197 1206
37. O.W. Prall, E.M. Rogan, and E.A. Musgrove c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry Mol Cell Biol 18 1998 4499 4508
38. B. Amati, and H. Land Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death Curr Opin Genet Dev 4 1994 102 108
39. J.M. Grad, J.L. Dai, and S. Wu Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA Mol Endocrinol 13 1999 1896 1911
40. J. Kokontis, K. Takakura, and N. Hay Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation Cancer Res 54 1994 1566 1573
41. R. Bookstein, P. Rio, and S.A. Madreperla Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma Proc Natl Acad Sci USA 87 1990 7762 7766
42. J. Geradts, S.X. Hu, and C.E. Lincoln Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies Int J Cancer 58 1994 161 167
43. J. Geradts, and P.A. Wilson High frequency of aberrant p16(INK4A) expression in human breast cancer Am J Pathol 149 1996 15 20
44. T. Susini, F. Baldi, and C. Howard Expression of the retinoblastoma- related gene Rb2/p130 correlates with clinical outcome in endometrial cancer J Clin Oncol 16 1998 1085 1093
45. M. Caputi, A.M. Groeger, and V. Esposito Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer Clin Cancer Res 8 2002 3850 3856
46. R.J. Cote, M.D. Dunn, and S.J. Chatterjee Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53 Cancer Res 58 1998 1090 1094
47. M.M. Ittmann, and R. Wieczorek Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas Hum Pathol 27 1996 28 34
48. J.D. Brooks, G.S. Bova, and W.B. Isaacs Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas Prostate 26 1995 35 39
49. S.M. Phillips, and C.M. Barton Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis Br J Cancer 70 1994 1252 1257
50. K.A. Cooney, J.C. Wetzel, and S.D. Merajver Distinct regions of allelic loss on 13q in prostate cancer Cancer Res 56 1996 1142 1145
51. J. Melamed, J.M. Einhorn, and M.M. Ittman Allelic loss on chromosome 13q in human prostate carcinoma Clin Cancer Res 3 1997 1867 1872
52. S. Vesalainen, and P. Lipponen Expression of retinoblastoma gene (Rb) protein in T1-2M0 prostatic adenocarcinoma J Cancer Res Clin Oncol 121 1995 429 433
53. C. Cordon-Cardo Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia Am J Pathol 147 1995 545 560
54. S.M. Henshall, D.I. Quinn, and C.S. Lee Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients Clin Cancer Res 7 2001 544 550
55. Y. Xiong, J. Menninger, and D. Beach Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins Genomics 13 1992 575 584
56. L.M. Gumbiner, P.H. Gumerlock, and P.C. Mack Overexpression of cyclin D1 is rare in human prostate carcinoma Prostate 38 1999 40 45
57. S. Aaltomaa, M. Eskelinen, and P. Lipponen Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival Prostate 38 1999 175 182
58. B.V. Kallakury, C.E. Sheehan, and R.A. Ambros The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma Cancer 80 1997 753 763
59. P.L. Porter, K.E. Malone, and P.J. Heagerty Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients Nature Med 3 1997 222 225
60. H. Iida, M. Towatari, and M. Tanimoto Overexpression of cyclin E in acute myelogenous leukemia Blood 90 1997 3707 3713
61. R.D. Mashal, S. Lester, and C. Corless Expression of cell cycle-regulated proteins in prostate cancer Cancer Res 56 1996 4159 4163
62. M. Serrano, G.J. Hannon, and D. Beach A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 366 1993 704 707
63. J.G. Herman, A. Merlo, and L. Mao Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all human cancers Cancer Res 55 1995 4525 4530
64. A. Komiya, H. Suzuki, and S. Aida Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer Jpn J Cancer Res 86 1995 622 625
65. D.F. Jarrard, G.S. Bova, and C.M. Ewing Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer Genes, Chromosomes Cancer 19 1997 90 96
66. P. Cairns, T.J. Polascik, and Y. Eby Frequency of homozygous deletion at p16/CDKN2 in primary human tumours Nature Genet 11 1995 210 212
67. Y. Tamimi, P.P. Bringuier, and F. Smit p16 mutations/deletions are not frequent events in prostate cancer Br J Cancer 74 1996 120 122
68. J.P. Gaddipati, D.G. McLeod, and I.A. Sesterhenn Mutations of the p16 gene product are rare in prostate cancer Prostate 30 1997 188 194
69. W. Chen, C.M. Weghorst, and C.L.K. Sabourin Absence of p 16/MTS 1 gene mutations in human prostate cancer Carcinogenesis 17 1996 2603 2607
70. D.J. Park, S.P. Wilczynski, and E.Y. Pham Molecular analysis of the INK4 family of genes in prostate carcinomas J Urol 157 1997 1995 1999
71. C.T. Lee, P. Capodieci, and I. Osman Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer Clin Cancer Res 5 1999 977 983
72. O.J. Halvorsen, J. Hostmark, and S. Haukaas Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma Cancer 88 2000 416 424
73. Y. Li, M.A. Nichols, and J.W. Shay Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb Cancer Res 54 1994 6078 6082
74. D.F. Jarrard, S. Sarkar, and Y. Shi p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells Cancer Res 59 1999 2957 2964
75. J. Tsihlias, L. Kapusta, and J. Slingerland The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer Annu Rev Med 50 1999 401 423
76. X. Gao, Y.Q. Chen, and N. Wu Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer Oncogene 11 1995 1395 1398
77. S. Rowan, R.L. Ludwig, and Y. Haupt Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant EMBO J 15 1996 827 838
78. J. Wang, and K. Walsh Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation Science 273 1996 359 361
79. I. Osman, M. Drobnjak, and M. Fazzari Inactivation of the p53 pathway in prostate cancer: impact on tumor progression Clin Cancer Res 5 1999 2082 2088
80. A. Russell, J. Hendley, and D. Germain Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins Oncogene 18 1999 6454 6459
81. S. Lu, M. Liu, and D.E. Epner Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter Mol Endocrinol 13 1999 376 384
82. J. Rigaud, R. Tiguert, and M. Decobert Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy Prostate 58 2004 269 276
83. K. Fizazi, L.A. Martinez, and C.R. Sikes The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer Clin Cancer Res 8 2002 775 781
84. M.V. Ponce-Castaneda, M.H. Lee, and E. Latres p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors Cancer Res 55 1995 1211 1214
85. M.L. Fero, M. Rivkin, and M. Tasch A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 (Kip1)-deficient mice Cell 85 1996 733 744
86. C. Cordon-Cardo, A. Koff, and M. Drobnjak Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma J Natl Cancer Inst 90 1998 1284 1291
87. C. Catzavelos, N. Bhattacharya, and Y.C. Ung Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer Nature Med 3 1997 227 230
88. R.V. Lloyd, L. Jin, and X. Qian Aberrant p27kip1 expression in endocrine and other tumors Am J Pathol 150 1997 401 407
89. P. Tan, B. Cady, and M. Wanner The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas Cancer Res 57 1997 1259 1263
90. S. Fredersdorf, J. Burns, and A.M. Milne High level expression of p27 (kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27 (kip1) and degree of malignancy in human breast and colorectal cancers Proc Natl Acad Sci USA 94 1997 6380 6385
91. V. Esposito, A. Baldi, and A. De Luca Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer Cancer Res 57 1997 3381 3385
92. M. Loda, B. Cukor, and S.W. Tam Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas Nature Med 3 1997 231 234
93. S.P. Singh, J. Lipman, and H. Goldman Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma Cancer Res 58 1998 1730 1735
94. N. Kawamata, R. Morosetti, and C.W. Miller Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies Cancer Res 55 1995 2266 2269
95. K.S. Spirin, J.F. Simpson, and S. Takeuchi p27/Kip1 mutation found in breast cancer Cancer Res 56 1996 2400 2404
96. A.S. Kibel, D. Freije, and W.B. Isaacs Deletion mapping at 12p12-13 in metastatic prostate cancer Genes Chromosomes Cancer 25 1999 270 276
97. M. Pagano, S.W. Tam, and A.M. Theodoras Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 Science 269 1995 682 685
98. S.S. Millard, J.S. Yan, and H. Nguyen Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest J Biol Chem 272 1997 7093 7098
99. J. Vlach, S. Hennecke, and B. Amati Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27 EMBO J 16 1997 5334 5344
100. L. Jin, X. Qian, and E. Kulig Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries Am J Pathol 151 1997 509 519
101. R. Vrhovac, A. Delmer, and R. Tang Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia Blood 91 1998 4694 4700
102. J. Vlach, S. Hennecke, and K. Alevizopoulos Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc EMBO J 15 1996 6595 6604
103. I. Perez-Roger, D.L. Solomon, and A. Sewing Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27 (Kip1) binding to newly formed complexes Oncogene 14 1997 2373 2381
104. D. Muller, C. Bouchard, and B. Rudolph Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes Oncogene 15 1997 2561 2576
105. R.J. Sheaff, M. Groudine, and M. Gordon Cyclin E-CDK2 is a regulator of p27Kip1 Genes Dev 11 1997 1464 1478
106. J.M. Kokontis, N. Hay, and S. Liao Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest Mol Endocrinol 12 1998 941 953
107. R.B. Myers, D.K. Oelschlager, and P.N. Coan Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma J Urol 161 1999 945 949
108. D.B. Agus, C. Cordon-Cardo, and W. Fox Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence J Natl Cancer Inst 91 1999 1869 1876
109. Y. Guo, G.N. Sklar, and A. Borkowski Loss of the cyclin-dependent kinase inhibitor p27Kip1 protein in human prostate cancer correlates with tumor grade Clin Cancer Res 3 1997 2269 2274
110. J. Tsihlias, L.R. Kapusta, and G. DeBoer Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma Cancer Res 58 1998 542 548
111. R.J. Cote, Y. Shi, and S. Groshen Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma J Natl Cancer Inst 90 1998 916 920
112. A.M. De Marzo, A.K. Meeker, and J.I. Epstein Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells Am J Pathol 153 1998 911 919
113. R.M. Yang, J. Naitoh, and M. Murphy Low p27 expression predicts poor disease-free survival in patients with prostate cancer J Urol 159 1998 941 945
114. M. Kuczyk, S. Machtens, and K. Hradil Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients Br J Cancer 81 1999 1052 1058
115. M.A. Kuczyk, C. Bokemeyer, and J. Hartmann Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer Oncol Rep 8 2001 1401 1407
116. M.L. Cher, D. MacGrogan, and R. Bookstein Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer Genes, Chromosomes Cancer 11 1994 153 162
117. M.L. Cher, G.S. Bova, and D.H. Moore Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping Cancer Res 56 1996 3091 3102
118. N.N. Nupponen, L. Kakkola, and P. Koivisto Genetic alterations in hormone-refractory recurrent prostate carcinomas Am J Pathol 153 1998 141 148
119. K. Sato, J. Qian, and J.M. Slezak Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma J Natl Cancer Inst 91 1999 1574 1580
120. J. Qian, R.B. Jenkins, and D.G. Bostwick Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization Mod Pathol 10 1997 1113 1119
121. S.B. Fox, R.A. Persad, and J. Royds p53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants? J Urol 150 1993 490 494
122. R.B. Jenkins, J. Qian, and M.M. Lieber Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization Cancer Res 57 1997 524 531
123. L. Bubendorf, J. Kononen, and P. Koivisto Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays [published erratum appears in Cancer Res 1999;59(6):1388] Cancer Res 59 1999 803 806
124. R. Buttyan, I.S. Sawczuk, and M.C. Benson Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers Prostate 11 1987 327 337
125. W.H. Fleming, A. Hamel, and R. MacDonald Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia Cancer Res 46 1986 1535 1538
126. D.G. Kirsch, and M.B. Kastan Tumor-suppressor p53: implications for tumor development and prognosis J Clin Oncol 16 1998 3158 3168
127. J.C. Reed Bcl-2 and the regulation of programmed cell death J Cell Biol 124 1994 1 6
128. T. Visakorpi, O.P. Kallioniemi, and A. Heikkinen Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation J Natl Cancer Inst 84 1992 883 887
129. A.J. Raffo, H. Perlman, and M.W. Chen Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo Cancer Res 55 1995 4438 4445
130. J.J. Bauer, I.A. Sesterhenn, and F.K. Mostofi Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer J Urol 156 1996 1511 1516
131. I. Apakama, M.C. Robinson, and N.M. Walter C. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer Br J Cancer 74 1996 1258 1262
132. F.J. Meyers, P.H. Gumerlock, and S.G. Chi Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors Cancer 83 1998 2534 2539
133. D.I. Quinn, S.M. Henshall, and D. Head Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy Cancer Res 60 2000 1585 1594
134. P. Stattin, P. Westin, and J.E. Damber Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer Br J Cancer 77 1998 670 675
135. O.W. Rokhlin, N. Guseva, and A. Tagiyev Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis Oncogene 20 2001 2836 2843
136. M.L. Agarwal, W.R. Taylor, and M.V. Chernov The p53 network J Biol Chem 273 1998 1 4
137. D.A. Liebermann, B. Hoffman, and R.A. Steinman Molecular controls of growth arrest and apoptosis: p53-dependent and independent markers Oncogene 11 1995 199 210
138. K.M. Dameron, O.V. Volpert, and M.A. Tainsky Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 Science 265 1994 1582 1584
139. G. Gasparini, N. Weidner, and P. Bevilacqua Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma J Clin Oncol 12 1994 454 466
140. E.D. Yu, E. Yu, and G.E. Meyer The relation of p53 protein nuclear accumulation and angiogenesis in human prostate cancer Prostate Cancer Prostate Dis 1 1997 39 44
141. J.H. Mydlo, J.G. Kral, and M. Volpe An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications Eur Urol 34 1998 426 432
142. C.A. Finlay, P.W. Hinds, and T.H. Tan Activating mutations for transformation by p53 produce a gene product that forms an hsc 70-p 53 complex withan altered half-life Mol Cell Biol 8 1988 531 539
143. J. Bartek, R. Iggo, and J. Gannon Genetic and immunochemical analysis of mutant p53 in human breast cacner cell lines Oncogene 5 1990 893 899
144. G. Casey, M.E. Lopez, and J.C. Ramos DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies Oncogene 13 1996 1971 1981
145. S.M. Bodner, J.D. Minna, and S.M. Jensen Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation Oncogene 7 1992 743 749
146. M.F. Melhem, J.C. Law, and L. el-Ashmawy Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers Am J Pathol 146 1995 1170 1177
147. C.A. Midgley, and D.P. Lane p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding Oncogene 15 1997 1179 1189
148. A.D. Thor, D.H. Moore, and S.M. Edgerton Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers J Natl Cancer Inst 84 1992 845 855
149. R.M. Elledge, G.M. Clark, and S.A. Fuqua p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer Cancer Res 54 1994 3752 3757
150. H.-J. Xu, P.T. Cagle, and S.-X. Hu Altered retinoblastoma amd p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis Clin Cancer Res 2 1996 1169 1176
151. H.-S. Goh, J. Yao, and D.R. Smith p53 point mutation and survival in colorectal cancer patients Cancer Res 55 1995 5217 5221
152. D.J. Grignon, R. Caplan, and F.H. Sarkar p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610 J Natl Cancer Inst 89 1997 158 165
153. M.A. Kuczyk, J. Serth, and C. Bokemeyer The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy Eur J Cancer 34 1998 679 686
154. J.J. Bauer, I.A. Sesterhenn, and K.F. Mostofi p53 nuclear protein expression is an independent prognostic marker in clinically localised prostate cancer patients undergoing radical prostatectomy Clin Cancer Res 1 1995 1295 1300
155. G. Yang, A.M.F. Stapleton, and T.M. Wheeler Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression Clin Cancer Res 2 1996 399 401
156. J.D. Brooks, G.S. Bova, and C.M. Ewing An uncertain role for p53 gene alterations in human prostate cancers Cancer Res 56 1996 3814 3822
157. N.M. Navone, P. Troncoso, and L.L. Pisters p53 protein accumulation and gene mutation in the progression of human prostate carcinoma J Natl Cancer Inst 85 1993 1657 1669
158. R. Bookstein, D. MacGrogan, and S.G. Hilsenbeck p53 is mutated in a subset of advanced-stage prostate cancers Cancer Res 53 1993 3369 3373
159. W.N. Dinjens, M.M. van der Weiden, and F.H. Schroeder Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer Int J Cancer 56 1994 630 633
160. S.G. Chi, R.W. deVere White, and F.J. Meyers p53 in prostate cancer: frequent expressed transition mutations J Natl Cancer Inst 86 1994 926 933
161. P.H. Gumerlock, S.G. Chi, and X.B. Shi p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network J Natl Cancer Inst 89 1997 66 71
162. A.M.F. Stapleton, T.L. Timme, and A.E. Gousse Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases Clin Cancer Res 3 1997 1389 1397
163. Bova GS. Molecular genetics of hormone refractory prostate cancer metastasis. In: Isaacs W, Nelso P, eds, Keystone Symposia: Breast and Prostate Cancer, Copper Mountain, CO; 1998 Keystone Symposia, Silverhorn, CO
164. H. Suzuki, D. Freije, and D.R. Nusskern Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues Cancer Res 58 1998 204 209
165. J.H. Hughes, M.B. Cohen, and R.A. Robinson p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma Mod Pathol 8 1995 462 466
166. J.A. Eastham, A.M.F. Stapleton, and A.E. Gousse Association of p53 mutations with metastatic prostate cancer Clin Cancer Res 1 1995 1111 1118
167. C. Rakozy, D.J. Grignon, and F.H. Sarkar Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy Mod Pathol 11 1998 892 899
168. N.J. Prendergast, M.R. Atkins, and E.C. Schatte p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma J Urol 155 1996 1685 1692
169. D. Mirchandani, J. Zheng, and G.J. Miller Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer Am J Pathol 147 1995 92 101
170. N. Konishi, Y. Hiasa, and H. Matsuda Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma Am J Pathol 147 1995 1112 1122
171. B.M. Geburek, T.A. Kollmorgen, and J. Qian Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization J Urol 157 1997 223 227
172. J. Qian, K. Hirasawa, and D.G. Bostwick Loss of p53 and c-myc overrepresentation in stage T (2-3) N (1-3) M (0) prostate cancer are potential markers for cancer progression Mod Pathol 15 2002 35 44
173. G.L. Griewe, R.C. Dean, and W. Zhang p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein Prostate Cancer Prostatic Dis 6 2003 281 285
174. M. Borre, B. Stausbol-Gron, and J. Overgaard p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting J Urol 164 2000 716 721
175. S. Haldar, C. Beatty, and Y. Tsujimoto The bcl-2 gene encodes a novel G protein Nature 342 1989 195 198
176. Y. Tsujimoto, and C.M. Croce Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma Proc Natl Acad Sci USA 83 1986 5214 5218
177. T.J. McDonnell, P. Troncoso, and S.M. Brisbay Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940 6944
178. M. Colombel, F. Symmans, and S. Gil Detection of the apoptosis- suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers Am J Pathol 143 1993 390 400
179. G.J. Berchem, M. Bosseler, and L.Y. Sugars Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells Cancer Res 55 1995 735 738
180. D.J. McConkey, G. Greene, and C.A. Pettaway Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line Cancer Res 56 1996 5594 5599
181. C.J. Rosser, A.O. Reyes, and F. Vakar-Lopez Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma Int J Radiat Oncol Biol Phys 56 2003 1 6
182. L.G. Horvath, S.M. Henshall, and C.S. Lee Frequent loss of estrogen receptor-beta expression in prostate cancer Cancer Res 61 2001 5331 5335
183. L.S. Gorelic, D.L. Lamm, and I. Ramzy Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients Cancer 60 1987 211 219
184. J.A. de Winter, J. Trapman, and A.O. Brinkmann Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry J Pathol 160 1990 329 332
185. M.V. Sadi, and E.R. Barrack Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy Cancer Surv 11 1991 195 215
186. T.H. van der Kwast, J. Schalken, and J.A. Ruizeveld de Winter Androgen receptors in endocrine-therapy-resistant human prostate cancer Int J Cancer 48 1991 189 193
187. G.W. Chodak, D.M. Kranc, and L.A. Puy Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate J Urol 147 1992 798 803
188. K.K. Miyamoto, S.A. McSherry, and G.A. Dent Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue J Urol 149 1993 1015 1019
189. J.A. Ruizeveld de Winter, P.J. Janssen, and H.M. Sleddens Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am J Pathol 144 1994 735 746
190. C. Magi-Galluzzi, X. Xu, and L. Hlatky Heterogeneity of androgen receptor content in advanced prostate cancer Mod Pathol 10 1997 839 845
191. W.D. Tilley, S.S. Lim-Tio, and D.J. Horsfall Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis Cancer Res 54 1994 4096 4102
192. H. Peterziel, Z. Culig, and J. Stober Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding Int J Cancer 63 1995 544 550
193. A. Hobisch, Z. Culig, and C. Radmayr Distant metastases from prostatic carcinoma express androgen receptor protein Cancer Res 55 1995 3068 3072
194. G.S. Prins, R.J. Sklarew, and L.P. Pertschuk Image analysis of androgen receptor immunostaining in prostate cancer accurately predict response to hormonal therapy J Urol 159 1998 641 649
195. P. Koivisto, J. Kononen, and C. Palmberg Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res 57 1997 314 319
196. P. Koivisto, M. Kolmer, and T. Visakorpi Androgen receptor gene and hormonal therapy failure of prostate cancer Am J Pathol 152 1998 1 9
197. E.O. Olapade-Olaopa, E.H. MacKay, and N.A. Taub Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma Clin Cancer Res 5 1999 569 576
198. H. Takeda, K. Akakura, and M. Masai Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma Cancer 77 1996 934 940
199. S.D. Sweat, A. Pacelli, and E.J. Bergstralh Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery J Urol 161 1999 1233 1237
200. S.D. Sweat, A. Pacelli, and E.J. Bergstralh Androgen receptor expression in prostatic intraepithelial neoplasia and cancer J Urol 161 1999 1229 1232
201. C.M. Wilson, J.E. Griffin, and J.D. Wilson Immunoreactive androgen receptor expression in subjects with androgen resistance J Clin Endocrinol Metab 75 1992 1474 1478
202. T. Visakorpi, E. Hyytinen, and P. Koivisto In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat Genet 9 1995 401 406
203. A.F. Olumi, G.D. Grossfeld, and S.W. Hayward Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium Cancer Res 59 1999 5002 5011
204. P. Koivisto, E. Hyytinen, and C. Palmberg Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy Am J Pathol 147 1995 1608 1614
205. S.M. Henshall, D.I. Quinn, and C.S. Lee Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer Cancer Res 61 2001 423 427
206. D.A. Wolf, T. Herzinger, and H. Hermeking Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen Mol Endocrinol 7 1993 924 936
207. T.C. Thompson, T.L. Timme, and D. Kadmon Genetic predisposition and mesenchymal-epithelial interactions in ras + myc-induced carcinogenesis in reconstituted mouse prostate Mol Carcinog 7 1993 165 179
208. C. Lee, S.M. Sintich, and E.P. Mathews Transforming growth factor-beta in benign and malignant prostate Prostate 39 1999 285 290
209. A. Kooistra, J.C. Romijn, and F.H. Schroder Stromal inhibition of epithelial cell growth in the prostate; overview of an experimental study Urol Res 25 Suppl. 2 1997 S97 S105
210. M. Gleave, J.T. Hsieh, and C.A. Gao Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts Cancer Res 51 1991 3753 3761
211. B. Planz, Q. Wang, and S.D. Kirley Androgen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen J Urol 160 1998 1850 1855
212. W. Lu, Y. Luo, and M. Kan Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate [published erratum appears in J Biol Chem 1999;274(39):28058] J Biol Chem 274 1999 12827 12834
213. A. Hobisch, I.E. Eder, and T. Putz Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor Cancer Res 58 1998 4640 4645
214. M.J. Gerdes, T.D. Dang, and M. Larsen Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells Endocrinology 139 1998 3569 3577
215. H.Y. Leung, P. Mehta, and L.B. Gray Keratinocyte growth factor expression in hormone insensitive prostate cancer Oncogene 15 1997 1115 1120
216. M.W. Kattan, S.F. Shariat, and B. Andrews The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer J Clin Oncol 21 2003 3573 3579
217. M.E. Taplin, G.J. Bubley, and T.D. Shuster Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393 1398
218. J. Veldscholte, C. Ris-Stalpers, and G.G. Kuiper A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem Biophys Res Commun 173 1990 534 540
219. J. Veldscholte, C.A. Berrevoets, and C. Ris-Stalpers The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens J Steroid Biochem Mol Biol 41 1992 665 669
220. H. Suzuki, K. Akakura, and A. Komiya Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome Prostate 29 1996 153 158
221. M.A. Fenton, T.D. Shuster, and A.M. Fertig Functional characterization of mutant androgen receptors from androgen-independent prostate cancer Clin Cancer Res 3 1997 1383 1388
222. M.E. Taplin, G.J. Bubley, and Y.J. Ko Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res 59 1999 2511 2515
223. C. Palmberg, P. Koivisto, and E. Hyytinen Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade Eur Urol 31 1997 216 219
224. W.D. Tilley, G. Buchanan, and T.E. Hickey Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence Clinical Cancer Res 2 1996 277 286
225. Z. Culig, A. Hobisch, and M.V. Cronauer Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone Mol Endocrinol 7 1993 1541 1550
226. J.P. Gaddipati, D.G. McLeod, and H.B. Heidenberg Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers Cancer Res 54 1994 2861 2864
227. J.P. Elo, L. Kvist, and K. Leinonen Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol J Clin Endocrinol Metab 80 1995 3494 3500
228. J.M. Bentel, and W.D. Tilley Androgen receptors in prostate cancer J Endocrinol 151 1996 1 11
229. C.S. Choong, M.J. Sturm, and J.A. Strophair Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly→Arg) that results in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels J Clin Endocrinol Metab 81 1996 236 243
230. J. Tan, Y. Sharief, and K.G. Hamil Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells Mol Endocrinol 11 1997 450 459
231. N. Craft, Y. Shostak, and M. Carey A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nat Med 5 1999 280 285
232. S. Yeh, H.K. Lin, and H.Y. Kang From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells Proc Natl Acad Sci USA 96 1999 5458 5463
233. J. Lu, and M. Danielsen Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein J Biol Chem 273 1998 31528 31533
234. P.A. Koivisto, and I. Rantala Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer J Pathol 187 1999 237 241
235. L. Jia, C.S. Choong, and C. Ricciardelli Androgen receptor signaling: mechanism of interleukin-6 inhibition Cancer Res 64 2004 2619 2626
236. S.O. Lee, W. Lou, and M. Hou Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway Oncogene 22 2003 7981 7988
237. D. Bernard, A. Pourtier-Manzanedo, and J. Gil Myc confers androgen-independent prostate cancer cell growth J Clin Invest 112 2003 1724 1731
238. G. Jenster The role of the androgen receptor in the development and progression of prostate cancer Semin Oncol 26 1999 407 421
239. H. Bonkhoff, U. Stein, and G. Aumuller Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas Prostate 29 1996 261 267
240. R.B. Myers, S. Srivastava, and D.K. Oelschlager Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma J Natl Cancer Inst 86 1994 1140 1145
241. R.B. Myers, D. Brown, and D.K. Oelschlager Elevated serum levels of p105 (erbB-2) in patients with advanced-stage prostatic adenocarcinoma Int J Cancer 69 1996 398 402
242. H.I. Scher, A. Sarkis, and V. Reuter Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms Clin Cancer Res 1 1995 545 550
243. D. Ye, J. Mendelsohn, and Z. Fan Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells Clin Cancer Res 5 1999 2171 2177
244. J.S. Ross, T. Nazeer, and K. Church Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis Cancer 72 1993 3020 3028
245. E.J. Kuhn, R.A. Kurnot, and I.A. Sesterhenn Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma J Urol 150 1993 1427 1433
246. S.B. Fox, R.A. Persad, and N. Coleman Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma Br J Urol 74 1994 214 220
247. B.V. Kallakury, C.E. Sheehan, and R.A. Ambros Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas J Clin Oncol 16 1998 1302 1309
248. T. Visakorpi New pieces to the prostate puzzle Nature Med 5 1999 264 265
249. H.F. Mark, D. Feldman, and S. Das Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer Exp Mol Pathol 66 1999 170 178
250. J. Morote, I. de Torres, and C. Caceres Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer Int J Cancer 84 1999 421 425
251. P.N. Lara Jr., K.G. Chee, and J. Longmate Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial Cancer 100 2004 2125 2131
252. T. Visakorpi, O.P. Kallioniemi, and T. Koivula Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas Mod Pathol 5 1992 643 648
253. K. Mellon, S. Thompson, and R.G. Charlton p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate J Urol 147 1992 496 499
254. D. Robinson, F. He, and T. Pretlow A tyrosine kinase profile of prostate carcinoma Proc Natl Acad Sci USA 93 1996 5958 5962
255. X. Lu, S.H. Park, and T.C. Thompson Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation Cell 70 1992 153 161
256. T.C. Thompson, S.H. Park, and T.L. Timme Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer Oncogene 10 1995 869 879
257. K. Fan Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of P21 protein as a predictor for bone metastasis J Urol 139 1988 318 322
258. D.M. Peehl, N. Wehner, and T.A. Stamey Activated Ki-ras oncogene in human prostatic adenocarcinoma Prostate 10 1987 281 289
259. J.W. Moul, P.A. Friedrichs, and R.S. Lance Infrequent RAS oncogene mutations in human prostate cancer Prostate 20 1992 327 338
260. M. Watanabe, T. Shiraishi, and R. Yatani International comparison on ras gene mutations in latent prostate carcinoma Intl J Cancer 58 1994 174 178
261. E.C. Bushman, R.N. Nayak, and W. Bushman Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue J Urol 153 1995 233 237
262. N. Konishi, Y. Hiasa, and T. Tsuzuki Comparison of ras activation in prostate carcinoma in Japanese and American men Prostate 30 1997 53 57
263. T. Shiraishi, T. Muneyuki, and K. Fukutome Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations Anticancer Res 18 1998 2789 2792
264. S. Ramaswamy, N. Nakamura, and F. Vazquez Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway Proc Natl Acad Sci USA 96 1999 2110 2115
265. J.R. Graff, B.W. Konicek, and A.M. McNulty Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression J Biol Chem 275 2000 24500 24505
266. J. Liang, J. Zubovitz, and T. Petrocelli PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest Nat Med 8 2002 1153 1160
267. A. Radu, V. Neubauer, and T. Akagi PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1 Mol Cell Biol 23 2003 6139 6149
268. A.W. Tolcher Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor J Urol 171 2004 S41 S43 (discussion S44)
269. P.K. Majumder, J.J. Yeh, and D.J. George Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model Proc Natl Acad Sci USA 100 2003 7841 7846
270. S. Wang, J. Gao, and Q. Lei Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 2003 209 221
271. J. Li, C. Yen, and D. Liaw PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
272. P. Cairns, K. Okami, and S. Halachmi Frequent inactivation of PTEN/MMAC1 in primary prostate cancer Cancer Res 57 1997 4997 5000
273. Y.E. Whang, X. Wu, and H. Suzuki Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression Proc Natl Acad Sci USA 95 1998 5246 5250
274. X. Wu, K. Senechal, and M.S. Neshat The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway Proc Natl Acad Sci USA 95 1998 15587 15591
275. M.E. McMenamin, P. Soung, and S. Perera Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage Cancer Res 59 1999 4291 4296
276. H. Huang, J.C. Cheville, and Y. Pan PTEN induces chemosensitivity in pten-mutated prostate cancer cells by suppression of bcl-2 expression J Biol Chem 276 2001 38830 38836
277. B. Nan, T. Snabboon, and E. Unni The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity J Mol Endocrinol 31 2003 169 183
278. J. Edwards, N.S. Krishna, and C.J. Witton Gene amplifications associated with the development of hormone-resistant prostate cancer Clin Cancer Res 9 2003 5271 5281
279. Y. Liao, R. Grobholz, and U. Abel Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer Int J Cancer 107 2003 676 680
280. S.N. Malik, M. Brattain, and P.M. Ghosh Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer Clin Cancer Res 8 2002 1168 1171
281. M. Takeichi Cadherin cell adhesion receptors as a morphogenetic regulator Science 251 1991 1451 1455
282. M.S. Steinberg, and M. Takeichi Experimental specification of cell sorting, tissue spreading, and specific spatial patterning by quantitative differences in cadherin expression Proc Natl Acad Sci USA 91 1994 206 209
283. Y. Shimoyama, A. Nagafuchi, and S. Fujita Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness Cancer Res 52 1992 5770 5774
284. S. Hirano, N. Kimoto, and Y. Shimoyama Identification of a neural alpha-catenin as a key regulator of cadherin function and multicellular organization Cell 70 1992 293 301
285. R. Umbas, J.A. Schalken, and T.W. Aalders Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer Cancer Res 52 1992 5104 5109
286. P.J. Richmond, A.J. Karayiannakis, and A. Nagafuchi Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival Cancer Res 57 1997 3189 3193
287. S. Aaltomaa, P. Lipponen, and M. Ala-Opas Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer Br J Cancer 80 1999 477 482
288. R. Umbas, W.B. Isaacs, and P.P. Bringuier Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer Int J Cancer 74 1997 374 377
289. L. Cheng, M. Nagabhushan, and T.P. Pretlow Expression of E-cadherin in primary and metastatic prostate cancer Am J Pathol 148 1996 1375 1380
290. K. Tomita, A. van Bokhoven, and G.J. van Leenders Cadherin switching in human prostate cancer progression Cancer Res 60 2000 3650 3654
291. M.J. Bussemakers, A. Van Bokhoven, and K. Tomita Complex cadherin expression in human prostate cancer cells Int J Cancer 85 2000 446 450
292. A.M. De Marzo, B. Knudsen, and K. Chan-Tack E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens Urology 53 1999 707 713
293. A.A. Bryden, A.J. Freemont, and N.W. Clarke Paradoxical expression of E-cadherin in prostatic bone metastases BJU Int 84 1999 1032 1034
294. I.K. Bukholm, J.M. Nesland, and A.L. Borresen-Dale Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients J Pathol 190 2000 15 19
295. H. Kuniyasu, R. Ukai, and D. Johnston The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy Clin Cancer Res 9 2003 2185 2194
296. R. Kuefer, M.D. Hofer, and J.E. Gschwend The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer Clin Cancer Res 9 2003 6447 6452
297. M.G. Rashid, M.G. Sanda, and C.J. Vallorosi Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate Cancer Res 61 2001 489 492
298. C.Y. Sasaki, H. Lin, and P.J. Morin Truncation of the extracellular region abrogrates cell contact but retains the growth-suppressive activity of E-cadherin Cancer Res 60 2000 7057 7065
299. J. Rios-Doria, K.C. Day, and R. Kuefer The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells J Biol Chem 278 2003 1372 1379
300. D.R. Rhodes, M.G. Sanda, and A.P. Otte Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer J Natl Cancer Inst 95 2003 661 668
301. E. Ruijter, C. van de Kaa, and T. Aalders Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group Mod Pathol 11 1998 276 281
302. S.F. Brewster, J.D. Oxley, and M. Trivella Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy J Urol 161 1999 1238 1243
303. R. Nusse, and H.E. Varmus Wnt genes Cell 69 1992 1073 1087
304. C.Y. Logan, and R. Nusse The Wnt signaling pathway in development and disease Annu Rev Cell Dev Biol 2004
305. J.R. Miller The Wnts Genome Biol 3 2002 3001 (reviews)
306. R.V. Iozzo, I. Eichstetter, and K.G. Danielson Aberrant expression of the growth factor Wnt-5A in human malignancy Cancer Res 55 1995 3495 3499
307. C. Wissmann, P.J. Wild, and S. Kaiser WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer J Pathol 201 2003 204 212
308. N. Sagara, G. Toda, and M. Hirai Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7 Biochem Biophys Res Commun 252 1998 117 122
309. D.R. Chesire, C.M. Ewing, and W.R. Gage In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis Oncogene 21 2002 2679 2694
310. A. de la Taille, M.A. Rubin, and M.W. Chen Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells Clin Cancer Res 9 2003 1801 1807
311. G. Chen, N. Shukeir, and A. Potti Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications Cancer 101 2004 1345 1356
312. L.G. Horvath, S.M. Henshall, and C.S. Lee Loss of nuclear beta-catenin predicts for a poorer prognosis in localized prostate cancer Int J Cancer 113 2005 415 422
313. L.G. Horvath, S.M. Henshall, and J.G. Kench Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro Clin Cancer Res 10 2004 615 625
314. D.J. Mulholland, J.T. Read, and P.S. Rennie Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis Oncogene 22 2003 5602 5613
315. A. Damalas, A. Ben-Ze'ev, and I. Simcha Excess beta-catenin promotes accumulation of transcriptionally active p53 EMBO J 18 1999 3054 3063
316. T. Sasaki, H. Suzuki, and K. Yagi Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor beta-induced repression of c-myc Cancer Res 63 2003 801 806
317. C. Ricciardelli, D.I. Quinn, and W.A. Raymond Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer Cancer Res 59 1999 2324 2328
318. C. Ricciardelli, K. Mayne, and P.J. Sykes Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer Clin Cancer Res 4 1998 963 971
319. C. Ricciardelli, K. Mayne, and P.J. Sykes Elevated stromal chondroitin sulfate glycoaminoglycan predicts progression in early stage prostate cancer Clin Cancer Res 3 1997 983 992
320. P.S. Nelson, S.R. Plymate, and K. Wang Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma Cancer Res 58 1998 232 236
321. M.A. Noordzij, G.J. van Steenbrugge, and F.H. Schroder Decreased expression of CD44 in metastatic prostate cancer Int J Cancer 84 1999 478 483
322. M.W. Jackson, J.M. Bentel, and W.D. Tilley Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia J Urol 157 1997 2323 2328
323. M.A. Silberman, A.W. Partin, and R.W. Veltri Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate Cancer 79 1997 772 779
324. N. Weidner, P.R. Carroll, and J. Flax Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 143 1993 401 409
325. M. Borre, B.V. Offersen, and B. Nerstrom Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting Br J Cancer 78 1998 940 944
326. M. Borre, B. Nerstrom, and J. Overgaard Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting Clin Cancer Res 6 2000 1882 1890
327. D. Strohmeyer, C. Rossing, and A. Bauerfeind Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer Prostate 45 2000 216 224
328. A. Fernandez, T. Udagawa, and C. Schwesinger Angiogenic potential of prostate carcinoma cells overexpressing bcl-2 J Natl Cancer Inst 93 2001 208 213
329. F.A. Ferrer, L.J. Miller, and A. Andrawis Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells Urology 51 1998 161 167
330. N.J. Mabjeesh, M.T. Willard, and C.E. Frederickson Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3prime-kinase/protein kinase B in prostate cancer cells Clin Cancer Res 9 2003 2416 2425
331. H. Kuniyasu, P. Troncoso, and D. Johnston Relative expression of type IV collagenae, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers Clin Cancer Res 6 2000 2295 2308
332. K.J. Kim, B. Li, and J. Winer Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844
333. I.B. Joseph, J.B. Nelson, and S.R. Denmeade Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue Clin Cancer Res 3 1997 2507 2511
334. R.J. Stewart, D. Panigrahy, and E. Flynn Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts J Urol 165 2001 688 693
335. S. Sordello, N. Bertrand, and J. Plouet Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens Biochem Biophys Res Commun 251 1998 287 290
336. H.Q. Miao, P. Lee, and H. Lin Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression Faseb J 14 2000 2532 2539
337. C. Richard, G. Kim, and Y. Koikawa Androgens modulate the balance between VEGF and angiopoietin expression in prostate epithelial and smooth muscle cells Prostate 50 2002 83 91
338. M.L. Gagnon, D.R. Bielenberg, and Z. Gechtman Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity Proc Natl Acad Sci USA 97 2000 2573 2578
339. M. Ruiz, C. Pettaway, and R. Song Activator protein 2a inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells Cancer Res 64 2004 631 638
340. L. Levine, J.A. Lucci 3rd, and B. Pazdrak Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells Cancer Res 63 2003 3495 3502
341. F.A. Ferrer, L.J. Miller, and R.I. Andrawis Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells J Urol 157 1997 2329 2333
342. R. Mazzucchelli, R. Montironi, and A. Santinelli Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients Prostate 45 2000 72 79
343. S. Chevalier, I. Defoy, and J. Lacoste Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis Mol Cell Endocrinol 189 2002 169 179
344. M.E. Harper, E. Glynne-Jones, and L. Goddard Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells Br J Cancer 74 1996 910 916
345. A.H. Ismail, W. Altaweel, and S. Chevalier Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer Can J Urol 11 2004 2146 2150
346. D.J. George, S. Halabi, and T.F. Shepard Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480 Clin Cancer Res 7 2001 1932 1936
347. E.J. Small, M. Meyer, and M.E. Marshall Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone J Clin Oncol 18 2000 1440 1450
348. L.W. Chan, M.A. Moses, and E. Goley Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy J Clin Oncol 22 2004 499 506
349. S.F. Shariat, V.A. Anwuri, and D.J. Lamb Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy J Clin Oncol 22 2004 1655 1663
350. D.J. George, M.M. Regan, and W.K. Oh Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer Urology 63 2004 327 332
351. M. Kohli, V. Kaushal, and H.J. Spencer Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer Urology 61 2003 765 769
352. W.D. Figg, E.A. Kruger, and D.K. Price Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer Invest New Drugs 20 2002 183 194
353. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611
354. J. Kollermann, and B. Helpap Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue Am J Clin Pathol 116 2001 115 121
355. J.B. Kearney, N.C. Kappas, and C. Ellerstrom The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis Blood 103 2004 4527 4535
356. M. Elkin, A. Orgel, and H.K. Kleinman An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1 J Natl Cancer Inst 96 2004 875 878
357. K. Shimizu, H. Kubo, and K. Yamaguchi Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer Cancer Sci 95 2004 328 333
358. M.W. Jackson, J.S. Roberts, and S.E. Heckford A potential autocrine role for vascular endothelial growth factor in prostate cancer Cancer Res 62 2002 854 859
359. P. Sweeney, T. Karashima, and S.J. Kim Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production Clin Cancer Res 8 2002 2714 2724
360. W.J. Huss, C.F. Hanrahan, and R.J. Barrios Angiogenesis and prostate cancer: identification of a molecular progression switch Cancer Res 61 2001 2736 2743
361. J. Dai, Y. Kitagawa, and J. Zhang Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein Cancer Res 64 2004 994 999
362. R. Li, M. Younes, and T.M. Wheeler Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate Prostate 58 2004 193 199
363. Y. Zeng, K. Opeskin, and M.E. Baldwin Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer Clin Cancer Res 10 2004 5137 5144
364. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 10869 10874
365. L.J. van't Veer, H. Dai, and M.J. van de Vijver Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
366. M.J. van de Vijver, Y.D. He, and L.J. van't Veer A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
367. D. Singh, P.G. Febbo, and K. Ross Gene expression correlates of clinical prostate cancer behavior Cancer Cell 1 2002 203 209
368. J. Lapointe, C. Li, and J.P. Higgins Gene expression profiling identifies clinically relevant subtypes of prostate cancer Proc Natl Acad Sci USA 101 2004 811 816
369. R.Y. Kirdani, L.J. Emrich, and E.J. Pontes A comparison of estrogen and androgen receptor levels in human prostatic tissue from patients with non-metastatic and metastatic carcinoma and benign prostatic hyperplasia J Steroid Biochem 22 1985 569 575
370. R. Umbas, W.B. Isaacs, and P.P. Bringuier Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer Cancer Res 54 1994 3929 3933
371. N. Morita, H. Uemura, and K. Tsumatani E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion Br J Cancer 79 1999 1879 1883
372. M. Wood, K. Fudge, and J.L. Mohler In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer Clin Exp Metastasis 15 1997 246 258
373. J. Luo, D.M. Lubaroff, and M.J. Hendrix Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection Cancer Res 59 1999 3552 3556
374. O.H. Sanchez-Sweatman, F.W. Orr, and G. Singh Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases Invasion Metastasis 18 1998 297 305
375. K. Ge, F. Minhas, and J. Duhadaway Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma Int J Cancer 86 2000 155 161
376. K.A. Cooney, J.C. Wetzel, and C.M. Consolino Identification and characterization of proximal 6q deletions in prostate cancer Cancer Res 56 1996 4150 4153
377. J.C. Alers, P.J. Krijtenburg, and K.J. Vissers Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias Genes, Chromosomes & Cancer 12 1995 241 250
378. J. Trapman, H.F. Sleddens, and M.M. van der Weiden Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer Cancer Res 54 1994 6061 6064
379. M.R. Emmert-Buck, C.D. Vocke, and R.O. Pozzatti Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia Cancer Res 55 1995 2959 2962
380. C.D. Vocke, R.O. Pozzatti, and D.G. Bostwick Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21 Cancer Res 56 1996 2411 2416
381. G.S. Bova, D. MacGrogan, and A. Levy Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer Genomics 35 1996 46 54
382. G.S. Bova, B.S. Carter, and M.J. Bussemakers Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer Cancer Res 53 1993 3869 3873
383. Y. Cabeza-Arvelaiz, T.C. Thompson, and J.L. Sepulveda LAPSER1: a novel candidate tumor suppressor gene from 10q24.3 Oncogene 20 2001 6707 6717
384. H. Ishii, R. Baffa, and S.I. Numata The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors Proc Natl Acad Sci USA 96 1999 3928 3933
385. N. Tsuchiya, Y. Kondo, and A. Takahashi Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer Am J Pathol 160 2002 1799 1806
386. C. Kaltz-Wittmer, U. Klenk, and A. Glaessgen FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy Lab Invest 80 2000 1455 1464
387. G. Perinchery, N. Bukurov, and K. Nakajima High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer Int J Cancer 83 1999 610 614
388. G. Narla, K.E. Heath, and H.L. Reeves KLF6, a candidate tumor suppressor gene mutated in prostate cancer Science 294 2001 2563 2566
389. H. Fukuhara, T. Maruyama, and S. Nomura Functional evidence for the presence of tumor suppressor gene on chromosome 10p15 in human prostate cancers Oncogene 20 2001 314 319
390. B.S. Carter, C.M. Ewing, and W.S. Ward Allelic loss of chromosomes 16q and 10q in human prostate cancer Proc Natl Acad Sci USA 87 1990 8751 8755
391. H. Matsuyama, Y. Pan, and S. Yoshihiro Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer Prostate 54 2003 103 111
392. M. Srivastava, L. Bubendorf, and V. Srikantan ANX7, a candidate tumor suppressor gene for prostate cancer Proc Natl Acad Sci USA 98 2001 4575 4580
393. H.E. Feilotter, M.A. Nagai, and A.H. Boag Analysis of PTEN and the 10q23 region in primary prostate carcinomas Oncogene 16 1998 1743 1748
394. M.A. Rubin, A. Gerstein, and K. Reid 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer Hum Pathol 31 2000 504 508
395. A. Latil, P. Morant, and G. Fournier CHC1-L, a candidate gene for prostate carcinogenesis at 13q14.2, is frequently affected by loss of heterozygosity and underexpressed in human prostate cancer Int J Cancer 99 2002 689 696
396. M.L. Cher, T. Ito, and N. Weidner Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH) J Urol 153 1995 249 254
397. R.R. Berges, J. Vukanovic, and J.I. Epstein Implication of cell kinetic changes during the progression of human prostatic cancer Clin Cancer Res 1 1995 473 480
398. H. Matsushima, T. Goto, and Y. Hosaka Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation Cancer 85 1999 1822 1827
399. P. Westin, P. Stattin, and J.E. Damber Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors Am J Pathol 146 1995 1368 1375
400. D. Theodorescu, S.R. Broder, and J.C. Boyd p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate J Urol 158 1997 131 137
401. S. Aaltomaa, P. Lipponen, and M. Eskelinen Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer Prostate 39 1999 8 15
402. H. Matsushima, T. Sasaki, and T. Goto Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance Hum Pathol 29 1998 778 783
403. J.C. Cheville, R.V. Lloyd, and T.J. Sebo Expression of p27kip1 in prostatic adenocarcinoma Mod Pathol 11 1998 324 328
404. S. Erdamar, G. Yang, and J.W. Harper Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis Mod Pathol 12 1999 751 755
405. M. Borre, B. Stausbol-Gron, and B. Nerstrom Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly Prostate Cancer Prostatic Dis 1 1998 268 275
406. M. Borre, B. Nerstrom, and J. Overgaard The natural history of prostate carcinoma based on a Danish population treated with no intent to cure Cancer 80 1997 917 928
407. G.B. Stackhouse, I.A. Sesterhenn, and J.J. Bauer p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy J Urol 162 1999 2040 2045
408. D.S. Scherr, E.D. Vaughan Jr., and J. Wei BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy [published erratum appears in J Urol 1999;162(2):503] J Urol 162 1999 12 16
409. M. Kuczyk, J. Serth, and S. Machtens Expression of E-cadherin in primary prostate cancer: correlation with clinical features Br J Urol 81 1998 406 412
410. J.S. Ross, H.L. Figge, and H.X. Bui E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome Mod Pathol 7 1994 835 841
411. J.A. Magee, T. Araki, and S. Patil Expression profiling reveals hepsin overexpression in prostate cancer Cancer Res 61 2001 5692 5696
412. S.M. Dhanasekaran, T.R. Barrette, and D. Ghosh Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822 826
413. S. Varambally, S.M. Dhanasekaran, and M. Zhou The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
414. M.D. Hofer, R. Kuefer, and S. Varambally The role of metastasis- associated protein 1 in prostate cancer progression Cancer Res 64 2004 825 829
415. M. Loda, F. Fogt, and F.S. French Androgen receptor immunohisto chemistry on paraffin-embedded tissue Med Pathol 7 3 1994 388 391